Presence of Cytotoxic B220+CD3+CD4 -CD8- Cells Correlates with the Therapeutic Efficacy of Lymphoma Treatment with IL-2 and/or IL-12

Journal of Immunotherapy

Volumn 27, Issue 2, 2004, Pages 107-115

  Masztalerz, Agnieszka ^a,b   Everse, Linda Ann ^a   Den Otter, Willem ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer; Interleukin 12; Interleukin 2

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; LYMPHOID CELL; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOMA; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

EID: 1442336028     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200403000-00004     Document Type: Article

References (29)

1. Den Otter W, Hill FW, Klein WR, et al. Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother. 1995;41:10-14.
2. Den Otter W, De Groot JW, Bernsen MR, et al. Optimal regimes for local IL-2 tumour therapy. Int J Cancer. 1996;66:400-403.
3. Maas RA, Dullens HF, De Jong WH, et al. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res. 1989;49:7037-7040.
4. Wigginton JM, Komschlies KL, Green JE, et al. Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination. Ann N Y Acad Sci. 1996;795:434-439.
5. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223-1230.
6. Lin JX, Leonard WJ. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 1997;8:313-332.
7. Koizumi S, Seki H, Tachinami T, et al. Malignant clonal expansion of large granular lymphocytes with a Leu- 11+, Leu-7-surface phenotype: in vitro responsiveness of malignant cells to recombinant human interleukin 2. Blood. 1986;68:1065-1073.
8. Grimm EA, Robb RJ, Roth JA, et al. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983;158:1356-1361.
9. Nishimura T, Watanabe K, Lee U, et al. Phenotypic and functional characteristics of in vivo-induced interleukin-12-activated killer cells. Immunol Lett. 1995;48:167-174.
10. Ogawa M, Tsutsui T, Zou JP, et al. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12. Cancer Res. 1997;57:2216-2222.
11. Hiraki A, Kiura K, Yamane H, et al. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer. 2002;35:329-333.
12. Kodama T, Takeda K, Shimozato O, et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol. 1999;29:1390-1396.
13. Takeda K, Hayakawa Y, Atsuta M, et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol. 2000;12:909-914.
14. Cui J, Shin T, Kawano T, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623-1626.
15. Bacon CM, McVicar DW, Ortaldo JR, et al. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med. 1995;181:399-404.
16. Desai BB, Quinn PM, Wolitzky AG, et al. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol. 1992;148:3125-3132.
17. Yanagida T, Kato T, Igarashi O, et al. Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol. 1994;152:4919-4928.
18. Chan SH, Perussia B, Gupta JW, et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 1991;173:869-879.
19. Gollob JA, Schnipper CP, Murphy EA, et al. The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol. 1999;162:4472-4481.
20. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90:2541-2548.
21. Mehrotra PT, Wu D, Crim JA, et al. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol. 1993;151:2444-2452.
22. DeBlaker-Hohe DF, Yamauchi A, Yu CR, et al. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol. 1995;165:33-43.
23. Den Otter W, Balemans L, Battermann JJ, et al. Local low-dose IL-2 therapy. Hepatogastroenterology. 1999;46(Suppl):1280-1286.
24. De Weger RA, Wilbrink B, Moberts RM, et al. Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice. Cancer Immunol Immunother. 1987;24:25-36.
25. Romagnani S, Manetti R, Annunziato F, et al. Role of IL12 in the development of human Th1 type cells. Res Immunol. 1995;146:452-460.
26. Barton DP, Blanchard DK, Duan C, et al. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral.blood mononuclear cells cultured in ovarian cancer ascitic fluid. J Soc Gynecol Investig. 1995;2:762-771.
27. Masztalerz A, Van Rooijen N, Den Otter W, et al. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother. 2003;52:235-242.
28. Gollob JA, Schnipper CP, Orsini E, et al. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998;102:561-575.
29. Tsutsui T, Mu J, Ogawa M, et al. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells. J Immunol. 1997;159:2599-2605.